{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T06:10:50Z","timestamp":1779343850844,"version":"3.51.4"},"reference-count":78,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint blockade (ICB) has revolutionized cancer treatment, including gynecological cancers, yet durable responses are observed only in subsets of patients. To improve efficacy, ICB is increasingly combined with complementary approaches. Although tissue-based biomarkers provide valuable information, their invasiveness and inability to capture systemic immune changes limit their utility. Peripheral blood offers a noninvasive alternative, but immune cell profiling in advanced cervical cancer (CC) and endometrial (EC) patients receiving ICB-based therapy remain underexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This exploratory translational study of the PRIMMO clinical trial (\n                      <jats:ext-link>https:\/\/clinicaltrials.gov\/search?id=%22NCT03192059%22<\/jats:ext-link>\n                      ) analyzed blood-based immune profiles from advanced CC (n=19) and EC (n=24) patients treated with an ICB-based regimen. Peripheral blood was collected at inclusion (baseline), on-treatment (week 7), and post-treatment (week 26 or earlier (&amp;lt; week 26) in case of earlier disease progression). Immune cell subsets and selected systemic immune mediators were assessed by multicolor flow cytometry and ELISA.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At baseline, CTLA-4\n                      <jats:sup>+<\/jats:sup>\n                      PD-1\n                      <jats:sup>+<\/jats:sup>\n                      CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells and CD161\n                      <jats:sup>+<\/jats:sup>\n                      CD56\n                      <jats:sup>+<\/jats:sup>\n                      CD16\n                      <jats:sup>+<\/jats:sup>\n                      NK cells were associated with survival outcomes only, while the combined immune score was associated with both treatment response and survival outcomes. During treatment, responders exhibited relatively stable immune profiles at both early and late treatment time points. In contrast, non-responders showed sustained decreases in pDCs and increases in activation (CD69, CD137, HLA-DR) and co-stimulatory\/inhibitory markers (CTLA-4, ICOS, Tim-3) across T cell subsets, including co-expression at both early and late phases of treatment. NK cell subsets also displayed increased activation features (CD69, CD161, HLA-DR). These changes were accompanied by expansion of immunoregulatory populations (MDSCs and Tregs), quantified based on phenotypic markers only, along with an increased kynurenine\/tryptophan ratio, and elevated sPD-1 levels. Tumor-type-specific analyses suggested relatively more NK-related changes in CC and T cell-related changes in EC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Longitudinal immune changes, rather than baseline differences alone, distinguished responders from non-responders. Non-response to the combination treatment is not characterized by immune inactivity but rather associated with sustained and coordinated increases in both activation and regulatory immune features, suggesting a shift toward systemic immune imbalance following treatment. These findings support the need for longitudinal, integrative immune monitoring strategies in future clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1794131","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:42:50Z","timestamp":1779342170000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Circulating immune cell profiling in advanced cervical and endometrial cancer patients treated with PD-1 blockade, radiotherapy, and immune modulation in the PRIMMO trial"],"prefix":"10.3389","volume":"17","author":[{"given":"Regina Esi Mensimah","family":"Baiden-Amissah","sequence":"first","affiliation":[{"name":"Gynecologic Oncology, Department of Oncology, Katholieke Universiteit Leuven (KU Leuven)","place":["Leuven, Belgium"]},{"name":"Leuven Cancer Institute","place":["Leuven, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Tuyaerts","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology, Department of Oncology, Katholieke Universiteit Leuven (KU Leuven)","place":["Leuven, Belgium"]},{"name":"Leuven Cancer Institute","place":["Leuven, Belgium"]},{"name":"Department of Medical Oncology, University Hospital Brussels","place":["Brussels, Belgium"]},{"name":"Translational Oncology Research Center (TORC), Vrije Universiteit Brussel","place":["Brussels, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Annibali","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology, Department of Oncology, Katholieke Universiteit Leuven (KU Leuven)","place":["Leuven, Belgium"]},{"name":"Leuven Cancer Institute","place":["Leuven, Belgium"]},{"name":"Gynecological Oncology, The Netherlands Cancer Institute","place":["Amsterdam, Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Herreros-Pomares","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology, Department of Oncology, Katholieke Universiteit Leuven (KU Leuven)","place":["Leuven, Belgium"]},{"name":"Leuven Cancer Institute","place":["Leuven, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wout","family":"De Wispelaere","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology, Department of Oncology, Katholieke Universiteit Leuven (KU Leuven)","place":["Leuven, Belgium"]},{"name":"Leuven Cancer Institute","place":["Leuven, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossana Maria","family":"Benedetto","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology, Department of Oncology, Katholieke Universiteit Leuven (KU Leuven)","place":["Leuven, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiel A.","family":"De Jaeghere","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ghent University Hospital","place":["Ghent, Belgium"]},{"name":"Cancer Research Institute Ghent (CRIG)","place":["Ghent, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An M. T.","family":"Van Nuffel","sequence":"additional","affiliation":[{"name":"Anticancer Fund","place":["Strombeek-Bever, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Vuylsteke","sequence":"additional","affiliation":[{"name":"Department of Hemato-Oncology, Centre Hospitalier Universitaire, Universit\u00e9 Catholique de Louvain Namur (Sainte-Elisabeth)","place":["Namur, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Henry","sequence":"additional","affiliation":[{"name":"Department of Hemato-Oncology, Centre Hospitalier Universitaire, Universit\u00e9 Catholique de Louvain Namur (Sainte-Elisabeth)","place":["Namur, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Bich Trinh","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology and Senology, University Hospital Antwerp","place":["Edegem, Belgium"]},{"name":"Multidisciplinary Oncologic Centre Antwerp (MOCA), University Hospital Antwerp","place":["Edegem, Belgium"]},{"name":"Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON)","place":["Edegem, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"Van Dam","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology and Senology, University Hospital Antwerp","place":["Edegem, Belgium"]},{"name":"Multidisciplinary Oncologic Centre Antwerp (MOCA), University Hospital Antwerp","place":["Edegem, Belgium"]},{"name":"Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON)","place":["Edegem, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Aspeslagh","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Hospital Brussels","place":["Brussels, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"De Caluw\u00e9","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Libre de Bruxelles (ULB), H\u00f4pitaux Universitaires de Bruxelles (H.U.B), Institut Jules Bordet","place":["Brussels, Belgium"]},{"name":"Department of Radiation Oncology, General Hospital Sint-Maarten","place":["Mechelen, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eline","family":"Naert","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ghent University Hospital","place":["Ghent, Belgium"]},{"name":"Cancer Research Institute Ghent (CRIG)","place":["Ghent, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrien","family":"Vandecasteele","sequence":"additional","affiliation":[{"name":"Cancer Research Institute Ghent (CRIG)","place":["Ghent, Belgium"]},{"name":"Department of Radiation Oncology, Ghent University Hospital","place":["Ghent, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannelore G.","family":"Denys","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ghent University Hospital","place":["Ghent, Belgium"]},{"name":"Cancer Research Institute Ghent (CRIG)","place":["Ghent, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Amant","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology, Department of Oncology, Katholieke Universiteit Leuven (KU Leuven)","place":["Leuven, Belgium"]},{"name":"Leuven Cancer Institute","place":["Leuven, Belgium"]},{"name":"Center for Gynecologic Oncology Amsterdam (CGOA), Netherlands Cancer Institute and Amsterdam Medical Center","place":["Amsterdam, Netherlands"]},{"name":"Department of Gynecology and Obstetrics, University Hospitals Leuven","place":["Leuven, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15164032","article-title":"Efficacy and safety of PD-1\/PD-L1 inhibitor as single-agent immunotherapy in endometrial cancer: A systematic review and meta-analysis","volume":"15","author":"Mamat Yusof","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.5526","article-title":"Efficacy and safety of enlonstobart (SG001), a PD-1 inhibitor in patients with PD-L1 positive recurrent\/metastatic cervical cancer: A multicenter, single-arm, open-label, phase II study","volume":"42","author":"Zuo","year":"2024","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1305810","article-title":"Clinical benefit analysis of PD-1 inhibitors in patients with advanced, recurrent or metastatic cervical cancer: a meta-analysis and systematic review","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.7150\/jca.17648","article-title":"Role of tumor microenvironment in tumorigenesis","volume":"8","author":"Wang","year":"2017","journal-title":"J Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01242-2","article-title":"Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation","volume":"15","author":"Wu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.17305\/bb.2025.12597","article-title":"The immunotherapy breakthroughs in cervical cancer: Focus on potential biomarkers and further therapy advances","volume":"25","author":"Pezer Naletili\u0107","year":"2025","journal-title":"Biomol BioMed"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(25)00167-6","article-title":"ESGO\u2013ESTRO\u2013ESP guidelines for the management of patients with endometrial carcinoma: update 2025","volume":"26","author":"Concin","year":"2025","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104555","article-title":"First-line treatments for advanced or recurrent endometrial cancer: Systematic literature review of clinical evidence","volume":"206","author":"Mirza","year":"2025","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2019.03.004","article-title":"Biochemical aspects of PD-L1 regulation in cancer immunotherapy","volume":"43","author":"Zhang","year":"2018","journal-title":"Trends Biochem Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.683419","article-title":"FDA-approved and emerging next generation predictive biomarkers for immune checkpoint inhibitors in cancer patients","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920937612","article-title":"Efficacy of PD-1\/PD-L1 blockade monotherapy in clinical trials","volume":"12","author":"Zhao","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030631","article-title":"Overview of immune checkpoint inhibitors in gynecological cancer treatment","volume":"14","author":"Pir\u0161","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007023","article-title":"Circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer","volume":"11","author":"Marcos Rubio","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123625","article-title":"Integrating circulating biomarkers in the immune checkpoint inhibitor treatment in lung cancer","volume":"12","author":"Duchemann","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B17","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-032-00763-6_130","article-title":"Predictive and on-treatment monitoring role of circulating biomarkers in immuno-oncology","volume-title":"Cancer diagnosis: tumor immunodiagnostic tests","author":"Malara","year":"2025"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.7150\/jca.65012","article-title":"Biomarkers for predicting the efficacy of immune checkpoint inhibitors","volume":"13","author":"Wang","year":"2022","journal-title":"J Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104332","article-title":"Circulating biomarkers as predictors of response to immune checkpoint inhibitors in NSCLC: Are we on the right path","volume":"197","author":"Spagnolo","year":"2024","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1186\/s12885-019-5676-3","article-title":"PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer","volume":"19","author":"Tuyaerts","year":"2019","journal-title":"BMC Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-21-0003","article-title":"Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy","volume":"12","author":"Herrera","year":"2022","journal-title":"Cancer Discov"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1074477","article-title":"Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2019.12.004","article-title":"Effects of radiation on the tumor microenvironment","volume":"30","author":"Monjazeb","year":"2020","journal-title":"Semin Radiat Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2021.0027","article-title":"Cyclophosphamide abrogates the expansion of CD4(+)Foxp3(+) regulatory T cells and enhances the efficacy of bleomycin in the treatment of mouse B16-F10 melanomas","volume":"18","author":"Li","year":"2021","journal-title":"Cancer Biol Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216441","article-title":"Metronomic chemotherapy, dampening of immunosuppressive cells, antigen presenting cell activation, and T cells. A quartet against refractoriness and resistance to checkpoint inhibitors","volume":"577","author":"Bravetti","year":"2023","journal-title":"Cancer Lett"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26104511","article-title":"Vitamin D and immune checkpoint inhibitors in lung cancer: A synergistic approach to enhancing treatment efficacy","volume":"26","author":"Zhang","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.173989","article-title":"Mechanisms of the antiangiogenic effects of aspirin in cancer","volume":"898","author":"Xie","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s12079-018-00499-y","article-title":"Aspirin suppresses tumor cell-induced angiogenesis and their incongruity","volume":"13","author":"Maity","year":"2019","journal-title":"J Cell Commun Signal"},{"key":"B29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.semcancer.2017.03.001","article-title":"Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation","volume":"43","author":"Huber","year":"2017","journal-title":"Semin Cancer Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13321","article-title":"Proton pump inhibitors display anti-tumour potential in glioma","volume":"56","author":"Li","year":"2023","journal-title":"Cell Prolif"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16142580","article-title":"The bright side of curcumin: A narrative review of its therapeutic potential in cancer management","volume":"16","author":"Amaroli","year":"2024","journal-title":"Cancers"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34718","article-title":"Vitamin D supplementation increases objective response rate and prolongs progression-free time in patients with advanced melanoma undergoing anti-PD-1 therapy","volume":"129","author":"Galus","year":"2023","journal-title":"Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.25891","article-title":"Does the combined use of aspirin and immunotherapy result in better outcomes in non-small cell lung cancer than immunotherapy alone","volume":"14","author":"Aiad","year":"2022","journal-title":"Cureus"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.675923","article-title":"Curcumin as an adjuvant to cancer immunotherapy","volume":"11","author":"Paul","year":"2021","journal-title":"Front Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1186\/s12885-024-12947-7","article-title":"Adverse reactions of immune checkpoint inhibitors combined with proton pump inhibitors: a pharmacovigilance analysis of drug-drug interactions","volume":"24","author":"Ren","year":"2024","journal-title":"BMC Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1070076","article-title":"Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis","volume":"14","author":"Lopes","year":"2023","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1259628","article-title":"The association between aspirin use and immune-related adverse events in specific cancer patients receiving ICIs therapy: analysis of the FAERS database","volume":"14","author":"Yang","year":"2023","journal-title":"Front Pharmacol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03253-x","article-title":"Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study","volume":"72","author":"De Jaeghere","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.10.020","article-title":"Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab: Insights from the phase II PRIMMO trial","volume":"191","author":"De Jaeghere","year":"2024","journal-title":"Gynecol Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"B41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1148\/radiology.143.1.7063747","article-title":"The meaning and use of the area under a receiver operating characteristic (ROC) curve","volume":"143","author":"Hanley","year":"1982","journal-title":"Radiology"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01398-3","article-title":"An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer","volume":"27","author":"Voabil","year":"2021","journal-title":"Nat Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1111344","article-title":"Increased levels of NETosis biomarkers in high-grade serous ovarian cancer patients\u2019 biofluids: Potential role in disease diagnosis and management","volume":"14","author":"Tom\u00e1s-P\u00e9rez","year":"2023","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2023.113514","article-title":"Impact of delayed PBMC processing on functional and genomic assays","volume":"519","author":"Yi","year":"2023","journal-title":"J Immunol Methods"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer\u2013immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","article-title":"Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations","volume":"24","author":"Butterfield","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","article-title":"Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours","volume":"24","author":"Holder","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.558248","article-title":"Immune cell profiling of peripheral blood as signature for response during checkpoint inhibition across cancer types","volume":"11","author":"Araujo","year":"2021","journal-title":"Front Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001845","article-title":"Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent\/metastatic cancer to immune checkpoint inhibitors","volume":"9","author":"Zhou","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1054161","article-title":"Baseline immune signature score of Tregs \u00d7 HLA-DR(+)CD4(+) T cells \u00d7 PD1(+)CD8(+) T cells predicts outcome to immunotherapy in cancer patients","volume":"13","author":"Mispelbaum","year":"2022","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.811091","article-title":"Immune dysfunctions of CD56(neg) NK cells are associated with HIV-1 disease progression","volume":"12","author":"Cao","year":"2021","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.816499","article-title":"Natural killer cells in the Malignant niche of multiple myeloma","volume":"12","author":"Venglar","year":"2021","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.886931","article-title":"Burgeoning exploration of the role of natural killer cells in anti-PD-1\/PD-L1 therapy","volume":"13","author":"Bai","year":"2022","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40364-026-00892-5","article-title":"Peripheral blood biomarkers for predicting response to PD-1\/PD-L1 inhibitors","volume":"14","author":"Chen","year":"2026","journal-title":"biomark Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"4487","DOI":"10.1038\/s41598-019-40933-8","article-title":"Circulating CD56(bright) NK cells inversely correlate with survival of melanoma patients","volume":"9","author":"de Jonge","year":"2019","journal-title":"Sci Rep"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007905","article-title":"NK cells CD56bright and CD56dim subset cytokine loss and exhaustion is associated with impaired survival in myeloma","volume":"6","author":"Seymour","year":"2022","journal-title":"Blood Adv"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1206631","article-title":"Dynamic evaluation of blood immune cells predictive of response to immune checkpoint inhibitors in NSCLC by multicolor spectrum flow cytometry","volume":"14","author":"Ma","year":"2023","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"Of1","DOI":"10.1158\/2159-8290.cd-24-1232","article-title":"Tumor-associated NK cells regulate distinct CD8+ T-cell differentiation program in cancer and contribute to resistance against immune checkpoint blockers","volume":"15","author":"Song","year":"2025","journal-title":"Cancer Discov"},{"key":"B60","doi-asserted-by":"publisher","first-page":"Of1","DOI":"10.1158\/2159-8290.cd-24-1208","article-title":"Cytotoxic NK cells impede response to checkpoint immunotherapy in melanoma with an immune-excluded phenotype","volume":"15","author":"Pozniak","year":"2025","journal-title":"Cancer Discov"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061650","article-title":"Role and potential of different T helper cell subsets in adoptive cell therapy","volume":"15","author":"Andreu-Sanz","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20241417","article-title":"CD4+ T cell dysfunction in cancer","volume":"222","author":"Venkatesh","year":"2025","journal-title":"J Exp Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.02.013","article-title":"Macrophage regulation of tumor responses to anticancer therapies","volume":"23","author":"De Palma","year":"2013","journal-title":"Cancer Cell"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxag002","article-title":"Circulating T-lymphocyte subsets as biomarkers for immune checkpoint inhibitors in solid tumors","volume":"220","author":"Kong","year":"2026","journal-title":"Clin Exp Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.875152","article-title":"Circulating T cell activation and exhaustion markers are associated with radiation pneumonitis and poor survival in non-small-cell lung cancer","volume":"13","author":"Berg","year":"2022","journal-title":"Front Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70255","article-title":"Predictive circulating biomarkers of the response to anti-PD-1 immunotherapy in advanced HER2 negative breast cancer","volume":"15","author":"Wei","year":"2025","journal-title":"Clin Transl Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03018-y","article-title":"Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1\/PD-L1 inhibitors","volume":"71","author":"Kang","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1065767","article-title":"Immunosuppressive capacity of circulating MDSC predicts response to immune checkpoint inhibitors in melanoma patients","volume":"14","author":"Petrova","year":"2023","journal-title":"Front Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.906815","article-title":"Dynamic change of IDO1 activity predicts survival in patients with unresectable stage III NSCLC and chemoradiotherapy","volume":"13","author":"Wu","year":"2022","journal-title":"Front Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjog.2023.10.002","article-title":"Immunotherapy that leverages HPV-specific immune responses for precancer lesions of cervical cancer","volume":"63","author":"Kobayashi","year":"2024","journal-title":"Taiwan J Obstetr Gynecol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.827921","article-title":"Biological characteristics and clinical significance of soluble PD-1\/PD-L1 and exosomal PD-L1 in cancer","volume":"13","author":"Niu","year":"2022","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2021.1926762","article-title":"Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients","volume":"10","author":"Machiraju","year":"2021","journal-title":"Oncoimmunology"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00017","article-title":"T cell dysfunction and exhaustion in cancer","volume":"8","author":"Zhang","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1233376","article-title":"Mechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy","volume":"13","author":"Lee","year":"2023","journal-title":"Front Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.21037\/aob-21-3","article-title":"A narrative review of immune checkpoint mechanisms and current immune checkpoint therapy","volume":"6","author":"Peng","year":"2021","journal-title":"Ann Blood"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13051521","article-title":"A systemic immune inflammation index and PD-L1 (SP142) expression as a potential combined biomarker of the clinical benefit of chemo-immunotherapy in extensive-stage small-cell lung cancer","volume":"13","author":"Baek","year":"2024","journal-title":"J Clin Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1200\/po.24.00100","article-title":"Combined transcriptome and circulating tumor DNA longitudinal biomarker analysis associates with clinical outcomes in advanced solid tumors treated with pembrolizumab","volume":"8","author":"Hernando-Calvo","year":"2024","journal-title":"JCO Precis Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1794131\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:42:51Z","timestamp":1779342171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1794131\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":78,"alternative-id":["10.3389\/fimmu.2026.1794131"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1794131","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"article-number":"1794131"}}